Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Atom Therapeutics Co., Ltd
Age
19–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have completed the double-blind Treatment Period in Study ABP-671-301 (Part 1 or Part 2) and are actively receiving and tolerating the study drug up to the Week 28 visit in Study ABP-671-301
You may not be if
Has a new medical or psychological condition that, in the opinion of the Investigator and/or Medical Monitor, might create undue risk to the participant, interfere with the participant's ability to comply with the protocol requirements to complete the Extension Study, or potentially compromise the results or interpretation of the Extension Study.
Is planning to become pregnant or breastfeed during the study or within ≤30 days after the last dose of the study drug.
Is intolerant or unwilling to take colchicine or naproxen.
Clareo Health | Extension Study of ABP-671 in Participants With Gout
